Abbott to develop companion diagnostic for Pfizer
This article was originally published in Clinica
Abbott’s molecular business is to provide Pfizer with a companion diagnostic test for screening non-small cell lung cancer (NSCLC) tumours for gene rearrangements. The new test will be used to determine whether or not patients are eligible to receive Pfizer’s PF-02341066 cancer drug. The drug is designed to selectively target genes that are implicated in a wide range of cancers. In order to receive PF-02341066, a patient’s NSCLC tumours must display a particular genetic rearrangement, which Abbott’s test will detect. Financial terms of the deal were not revealed.